搜索
(,246003)CCMD222R,BPRS18,12wk,8wk,4130,BPRS,9716%,8514%;9010%,7313%;;;;Comparisonoftherapeuticeffectbetweenrisperidoneinthetreatmentpatientswithfirst2outsetschizophreniaandexchangeconventionaldrugsforrisperidoneinthetreatmentpatientswithschizophreniaQIANJian2Ming(AnqingMentalHospital246003)ABSTRACTAIMTocomparisonoftherapeuticeffectbetweenrisperidoneinthetreatmentpatientswithfirst2outsetschizophreniaandexchangeconventionaldrugsforrisperidoneinthetreatmentpatientswithschizophrenia.METHODSeventy2onesubjectswithdiagnosisofschizophreniaaccordingtoCCMD222RandBPRS18weretreated.41patientswithfirst2outsetschizophreniaweregivenrisperidone(first2outsetgroup).30patientswithschizophreniacompletedtreatmentrisperidoneinsteadofconventionaldrugs(ex2changegroup).Aftertreatment12weeks,wecancomparetherapeuticefectineverygroupandbetweentwogroupswithBPRSandCGI.RESUITRisperidoneinthetreatmentpatientswithschizophreniawaseffective.Theeffectiverateoffirst2outsetgroupandex2changegroupwas9716%and9010%respectively,themarkedeffectiveratewas8514%and7313%respectively.CONCLUSIONEfficacyofthefirst2outsetgroupsignificantlybetterthantheexchangegroup.KEYWORDSrisperidone;schizophrenia;first2outsetgroup;exchangegroup;efficacy(Risperridone,),52HT2AD2,1994,1997,,(),8718%,6417%,1200012wk4130,1CCMD222R,BPRS188wk,413041,28,13,1638(2618615),36(117119),1438(2511613),02(015017),38,3,3011,331,1030,15,15,1350(3115814),320(515612),1232(2517513),04(113111),26,4,219,615,15t,,(P0101),,,(P0105)2211,0154mgd-1,330d,0158mgd-1,,1wk,1mgwk-1,212BPRS13AnhuiMedicalandPharmaceuticalJournal2002Mar;6(1)1BPRS( xs)BPRS58.713.720.02.03365.416.922.13.73311.63.35.01.13310.92.84.81.03311.42.75.01.83311.73.25.12.13314.34.24.71.03314.64.54.71.1338.73.13.40.8338.63.63.30.93311.43.03.40.83311.73.33.50.933:33P01012BPRS( xs)BPRS58.713.765.416.920.02.022.13.73311.63.310.92.85.01.14.81.011.42.711.73.25.01.85.12.114.34.214.64.54.71.04.71.08.73.18.63.63.40.83.30.911.43.011.73.33.40.83.50.9:33P01013CGI( xs)(SI)5.40.91.40.535.51.11.60.633(GI)4.01.01.10.333.51.91.30.533(EI)1.11.33.70.730.90.93.50.933:33P01014CGI( xs)(SI)5.40.95.51.11.40.51.60.6(GI)4.01.03.51.91.10.31.30.53(EI)1.11.30.90.93.70.73.50.9:3P0105CGI,12wkBPRS,75%,50%75%,25%50%,25%213BPRSCGIt3BPRS,4112wk6415715,1212%(5/41),8514%(35/41),214%(1/41),0(0/41),9716%3012wk63181111,1617%(5/30),7313%(22/30),1010%(3/30),0(0/30),9010%BPRSt(P0101),1,BPRStBPRS(P0101),(P0101),2CGI,41(SI),(GI)23AnhuiMedicalandPharmaceuticalJournal2002Mar;6(1)(236604)1(CHF)76CHFX,12550mgd-1,,,12wk12wkXCHFXCHF,1;;;;TheclinicalefficacyofbetalocfortreatmentofcongestiveheartfailureGAOXu(Taihecountrypeoplehospital,Taihe236604,Anhuiprovince,China)ABSTRACTAIMToevaluatetheclinicaltherapeuticefficacyof2receptorblolkerbetalocfortreatmentofcongestiveheartfailure.METHODSSeventy2sixpatientswithcongestiveheartfailurewererandomizedtotakedoseofbetaloc(2550mgperdayn=38)andtoplacebo(n=38)onthebacisofcoventionaltreatment(digoxin,diureticandangiotensincovertingenzgmeinhibitor).Themeanoffollowupperiodswas84days.Theefficacyofbetalocwasassessedbymeansofechoardiographyandclinicalsymptoms.RESULTAfterbetalocadimistrationfor12weeks,thereweremoresignificantimprovementNYHAfunctionalclassinbetalocgroupthaninplacebogroup.Betalocwasassociatedwithgreateroverallreductionofleftventricularend2diastolicandend2systolicdiameter.CON2CLUSIONLong2termadditionofbetaloctostandardtherapymayprofoundlyimprovecardiacfunctionandprognosisandpreventclini2caldeteriorationinpatientswithcongestiveheartfailurewhencomparedwithpatientswithoutbetaloctreatment.KEYWORDS2receptorblolker;betaloc;congestiveheartfailure;cardiacfunction;echocardiography1,(CHF),CHF38,,11111999320018CHF76,38,25,13,3476,54615,12,8,3NYHA(),4,21,13CHF1438,27,11,3675,52716,11,7,45,23,10,CHF0155,(EI)11111331701730(SI),(GI),(EI)019019315019SIGIEIt(P0101),3,SIGIEItGI(P0105),SIEI(P0101),4441()30(),,,,,12wk,,,,,,2,,,,,1,..,1999;11(4):2462,,etal..,1999;11(4):19933AnhuiMedicalandPharmaceuticalJournal2002Mar;6(1)